StockNews.com Initiates Coverage on Clovis Oncology (NASDAQ:CLVS)
StockNews.com Initiates Coverage on Clovis Oncology (NASDAQ:CLVS)
Analysts at StockNews.com began coverage on shares of Clovis Oncology (NASDAQ:CLVS – Get Rating) in a research note issued to investors on Monday. The firm set a "hold" rating on the biopharmaceutical company's stock.
StockNews.com的分析师在周一向投资者发布的一份研究报告中开始报道克洛维斯肿瘤学（纳斯达克股票代码：CLVS — 获取评级）的股票。该公司对这家生物制药公司的股票设定了 “持有” 评级。
Separately, JPMorgan Chase & Co. downgraded Clovis Oncology from a "neutral" rating to an "underweight" rating in a research report on Wednesday, November 9th.
另外，摩根大通在11月9日星期三的一份研究报告中将Clovis Oncology的评级从 “中性” 下调至 “减持” 评级。
Clovis Oncology Stock Down 18.5 %
克洛维斯肿瘤学股票下跌18.5％
CLVS stock opened at $0.08 on Monday. The firm has a market capitalization of $11.60 million, a PE ratio of -0.04 and a beta of 0.24. Clovis Oncology has a twelve month low of $0.08 and a twelve month high of $3.32. The stock has a 50-day simple moving average of $0.62 and a two-hundred day simple moving average of $1.16.
周一，CLVS股票开盘价为0.08美元。该公司的市值为1160万美元，市盈率为-0.04，贝塔值为0.24。克洛维斯肿瘤学的十二个月低点为0.08美元，十二个月高点为3.32美元。该股的50天简单移动平均线为0.62美元，两百天简单移动平均线为1.16美元。
Institutional Trading of Clovis Oncology
克洛维斯肿瘤学的机构交易
A number of hedge funds have recently bought and sold shares of CLVS. Vanguard Group Inc. lifted its position in Clovis Oncology by 22.1% in the 1st quarter. Vanguard Group Inc. now owns 12,348,898 shares of the biopharmaceutical company's stock worth $24,945,000 after buying an additional 2,233,797 shares during the last quarter. Millennium Management LLC lifted its position in Clovis Oncology by 49.9% in the 2nd quarter. Millennium Management LLC now owns 5,400,324 shares of the biopharmaceutical company's stock worth $9,721,000 after buying an additional 1,798,313 shares during the last quarter. Renaissance Technologies LLC lifted its position in Clovis Oncology by 139.2% in the 1st quarter. Renaissance Technologies LLC now owns 1,459,900 shares of the biopharmaceutical company's stock worth $2,949,000 after buying an additional 849,500 shares during the last quarter. Palo Alto Investors LP lifted its position in Clovis Oncology by 11.9% in the 1st quarter. Palo Alto Investors LP now owns 4,473,967 shares of the biopharmaceutical company's stock worth $9,037,000 after buying an additional 476,141 shares during the last quarter. Finally, Marshall Wace LLP lifted its position in Clovis Oncology by 259.6% in the 3rd quarter. Marshall Wace LLP now owns 310,123 shares of the biopharmaceutical company's stock worth $370,000 after buying an additional 223,880 shares during the last quarter. Institutional investors own 29.47% of the company's stock.
许多对冲基金最近买入和出售了CLVS的股票。Vanguard Group Inc.在第一季度将其在克洛维斯肿瘤学的头寸提高了22.1％。Vanguard Group Inc.在上个季度又购买了2,233,797股股票后，现在拥有这家生物制药公司的12,348,898股股票，价值24,945,000美元。千禧管理有限责任公司在第二季度将其在克洛维斯肿瘤学的头寸提高了49.9％。千禧管理有限责任公司在上个季度又购买了1,798,313股股票后，现在拥有这家生物制药公司的5,400,324股股票，价值9,721,000美元。复兴科技有限责任公司在第一季度将其在克洛维斯肿瘤学的头寸提高了139.2％。Renaissance Technologies LLC在上个季度又购买了849,500股股票后，现在拥有这家生物制药公司的1,459,900股股票，价值29.49万美元。帕洛阿尔托投资有限责任公司在第一季度将其在克洛维斯肿瘤学的头寸上调了11.9％。帕洛阿尔托投资有限责任公司在上个季度又购买了476,141股股票后，现在拥有这家生物制药公司的4,473,967股股票，价值9,037,000美元。最后，马歇尔·韦斯律师事务所在第三季度将其在克洛维斯肿瘤学中的地位提高了259.6％。马歇尔·韦斯律师事务所上个季度又购买了223,880股股票后，现在拥有这家生物制药公司的310,123股股票，价值37万美元。机构投资者拥有该公司29.47％的股票。
Clovis Oncology Company Profile
克洛维斯肿瘤公司简介
(Get Rating)
（获取评级）
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Clovis Oncology, Inc是一家生物制药公司，专注于在美国、欧洲和国际上收购、开发和商业化抗癌药物。其商业产品包括Rubraca（rucaparib）片剂，这是一种小分子聚ADP-核糖聚合酶抑制剂，用作单一疗法，用于治疗与有害BRCA突变相关的晚期卵巢癌患者，这些患者已经接受了两种或更多化疗的治疗，并由美国食品药品管理局批准的Rubraca伴随诊断机构选择进行治疗。
Featured Stories
精选故事
- Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
- How Do Chipmakers Stack Up When It Comes To Growth?
- Is AMC Entertainment Stock Worth Taking Down Here?
- Is it Time to Take a Bite into Domino's Pizza?
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- 免费获取 StockNews.com 关于克洛维斯肿瘤学（CLVS）的研究报告
- 在增长方面，芯片制造商如何站稳脚跟？
- AMC Entertainment的股票值得在这里下跌吗？
- 是时候吃一口达美乐披萨了吗？
- MarketBeat：本周回顾 12 月 12 日 — 12 月 16 日
- 哪两家蓝筹科技公司提高了指导方针？
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接收克洛维斯肿瘤学日报的新闻和评级-在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收克洛维斯肿瘤学及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。